This HTML5 document contains 58 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00843989%3A_____%2F12%3A00103107%21RIV13-MZ0-00843989/
n16http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n18http://linked.opendata.cz/resource/domain/vavai/subjekt/
n7http://linked.opendata.cz/ontology/domain/vavai/
n15http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n12http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n9http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00843989%3A_____%2F12%3A00103107%21RIV13-MZ0-00843989
rdf:type
n7:Vysledek skos:Concept
dcterms:description
We assessed long-term outcome of 118 consecutive patients in chronic phase of chronic myeloid leukemia (CML) treated with interferon-alpha (IFN-alpha) in the Central and Northern Moravia region between 1989 and 2006 with focus on operational cure. The median follow-up was 82.6 months (range 12.4-212.6). Eighteen (15.3%) patients achieved complete cytogenetic response (CCyR) after median 16.7 (3.7-40.8) months. Nine of these patients (7.6%) achieved BCR-ABL negativity in nested reverse transcriptase-polymerase chain reaction [%22complete'' molecular response (CMR)] and 6 of them have been operationally cured without any treatment for median 6 (4-10) years, while 2 continue with IFN-alpha and 1 died from CML-unrelated cause. Operationally cured patients had a significantly lower percentage of initial peripheral promyelocytes, blasts, and erythroblasts than the rest of patients treated for more than 12 months (P=0.01-0.03). Unlike patients with sole CCyR, the majority of whom lost CCyR despite continuing IFN-alpha therapy and required imatinib, patients who achieved CMR had excellent long-term outcome. We assessed long-term outcome of 118 consecutive patients in chronic phase of chronic myeloid leukemia (CML) treated with interferon-alpha (IFN-alpha) in the Central and Northern Moravia region between 1989 and 2006 with focus on operational cure. The median follow-up was 82.6 months (range 12.4-212.6). Eighteen (15.3%) patients achieved complete cytogenetic response (CCyR) after median 16.7 (3.7-40.8) months. Nine of these patients (7.6%) achieved BCR-ABL negativity in nested reverse transcriptase-polymerase chain reaction [%22complete'' molecular response (CMR)] and 6 of them have been operationally cured without any treatment for median 6 (4-10) years, while 2 continue with IFN-alpha and 1 died from CML-unrelated cause. Operationally cured patients had a significantly lower percentage of initial peripheral promyelocytes, blasts, and erythroblasts than the rest of patients treated for more than 12 months (P=0.01-0.03). Unlike patients with sole CCyR, the majority of whom lost CCyR despite continuing IFN-alpha therapy and required imatinib, patients who achieved CMR had excellent long-term outcome.
dcterms:title
Operational cures after interferon-alpha in patients with chronic myeloid leukemia in Central and Northern Moravia Operational cures after interferon-alpha in patients with chronic myeloid leukemia in Central and Northern Moravia
skos:prefLabel
Operational cures after interferon-alpha in patients with chronic myeloid leukemia in Central and Northern Moravia Operational cures after interferon-alpha in patients with chronic myeloid leukemia in Central and Northern Moravia
skos:notation
RIV/00843989:_____/12:00103107!RIV13-MZ0-00843989
n7:predkladatel
n18:ico%3A00843989
n3:aktivita
n10:S n10:V n10:Z
n3:aktivity
S, V, Z(MSM6198959205), Z(MSM6198959223)
n3:cisloPeriodika
5
n3:dodaniDat
n9:2013
n3:domaciTvurceVysledku
n16:1597442 n16:1383914 n16:1239031
n3:druhVysledku
n4:J
n3:duvernostUdaju
n14:S
n3:entitaPredkladatele
n6:predkladatel
n3:idSjednocenehoVysledku
156679
n3:idVysledku
RIV/00843989:_____/12:00103107
n3:jazykVysledku
n19:eng
n3:klicovaSlova
chronic myelogenous leukemia; fusion gene transcripts; residual disease; responses; imatinib; cells
n3:klicoveSlovo
n5:chronic%20myelogenous%20leukemia n5:imatinib n5:residual%20disease n5:cells n5:fusion%20gene%20transcripts n5:responses
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[7713205F6660]
n3:nazevZdroje
Journal of interferon & cytokine research
n3:obor
n13:FD
n3:pocetDomacichTvurcuVysledku
3
n3:pocetTvurcuVysledku
58
n3:rokUplatneniVysledku
n9:2012
n3:svazekPeriodika
32
n3:tvurceVysledku
Kuba, A. Zapletalová, J. Rožmanová, Š. Divoká, M. Holzerová, M. Rohoň, P. Gumulec, Jaromír Jarošová, M. Indrák, K. Faber, E. Matuška, Milan Blahutová, Šárka
n3:wos
000304312600006
n3:zamer
n15:MSM6198959205 n15:MSM6198959223
s:issn
1079-9907
s:numberOfPages
5
n12:doi
10.1089/jir.2011.0108